Neurogene (NGNE) Revenue (2018 - 2024)
Neurogene (NGNE) reported Revenue of $925000.0 for Q2 2024, down 99.91% quarter-over-quarter from $1.0 billion in Q3 2019.
Neurogene (NGNE) Revenue (2018 - 2024) Analysis & Trends
Neurogene has reported Revenue for 3 years, with the latest figure at $925000.0 in Q2 2024.
- For the quarter ending Q2 2024, Revenue changed N/A year-over-year to $925000.0; the trailing twelve-month figure through Jun 2025 stood at $925000.0 (changed 0.0% YoY), and the FY2024 full-year result was $925000.0, changed N/A from the prior year.
- Revenue for Q2 2024 stood at $925000.0, down from $1.0 billion in the prior quarter.
- The five-year high for Revenue was $925000.0 in Q2 2024, with the low at $925000.0 in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 5.21 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 306.30 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 2.99 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 925,000.00 |
| Sep 30, 2019 | 1.00 Bn |
| Jun 30, 2018 | 25.00 Mn |